📊 NUVB Key Takeaways
Is NUVB a Good Investment? Thesis Analysis
Nuvation Bio is a pre-revenue pharmaceutical company with severe cash burn (-$173.4M operating cash flow) that will deplete its $164.1M cash position within 12 months without significant capital raises or revenue inflection. Despite modest revenue of $62.9M with flat YoY growth and a 20.7% gross margin, the company hemorrhages cash with -$325.3% net margin and -275.7% FCF margin, indicating an unsustainable business model with no clear path to profitability.
Why Buy NUVB? Key Strengths
- Strong liquidity position with $164.1M cash and 6.95x current ratio providing runway for operations
- Low leverage with 0.15x debt-to-equity ratio limiting financial distress risk from debt obligations
- Positive gross margin of 20.7% demonstrates underlying product economics are viable at production level
NUVB Investment Risks to Consider
- Severe cash burn of $173.4M annually will exhaust cash reserves in approximately 12 months, forcing dilutive financing or operational shutdown
- Persistent operating losses of -$213.1M despite $62.9M revenue indicate R&D-heavy model with no near-term profitability pathway
- Flat revenue growth (0.0% YoY) combined with increasing net losses (-325.3% margin) shows deteriorating operational efficiency and failed commercialization
- Negative interest coverage of -21.0x indicates insufficient operating income to service debt obligations
- High insider trading activity (10 Form 4 filings in 90 days) may signal executive concern about company trajectory
Key Metrics to Watch
- Operating cash flow trend and months of cash runway remaining
- Revenue growth acceleration and gross margin sustainability
- Operating loss reduction rate and path to operating profitability
- Capital raise announcements and dilution impact on existing shareholders
- Pipeline milestone achievements and clinical trial progression
NUVB Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 6.95x current ratio provides a solid financial cushion.
NUVB Profitability Ratios
NUVB vs Healthcare Sector
How Nuvation Bio Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NUVB Overvalued or Undervalued?
Based on fundamental analysis, Nuvation Bio Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NUVB Balance Sheet & Liquidity
NUVB 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Nuvation Bio Inc.'s revenue has grown significantly by 699% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.11 indicates the company is currently unprofitable.
NUVB Growth Metrics (YoY)
NUVB Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $727.0K | -$14.8M | $-0.15 |
| Q2 2025 | $1.4M | -$14.8M | $-0.17 |
| Q1 2025 | N/A | -$14.8M | $-0.07 |
| Q3 2024 | N/A | -$14.8M | $-0.09 |
| Q2 2024 | N/A | -$14.8M | $-0.09 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NUVB Capital Allocation
NUVB SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Nuvation Bio Inc. (CIK: 0001811063)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 3, 2026 | 4 | xslF345X05/form4-03042026_010341.xml | View → |
| Mar 3, 2026 | 4 | xslF345X05/form4-03042026_010328.xml | View → |
| Mar 3, 2026 | 4 | xslF345X05/form4-03042026_010334.xml | View → |
| Mar 3, 2026 | 4 | xslF345X05/form4-03042026_010344.xml | View → |
| Mar 3, 2026 | 4 | xslF345X05/form4-03042026_010301.xml | View → |
❓ Frequently Asked Questions about NUVB
What is the AI rating for NUVB?
Nuvation Bio Inc. (NUVB) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NUVB's key strengths?
Claude: Strong liquidity position with $164.1M cash and 6.95x current ratio providing runway for operations. Low leverage with 0.15x debt-to-equity ratio limiting financial distress risk from debt obligations.
What are the risks of investing in NUVB?
Claude: Severe cash burn of $173.4M annually will exhaust cash reserves in approximately 12 months, forcing dilutive financing or operational shutdown. Persistent operating losses of -$213.1M despite $62.9M revenue indicate R&D-heavy model with no near-term profitability pathway.
What is NUVB's revenue and growth?
Nuvation Bio Inc. reported revenue of $62.9M.
Does NUVB pay dividends?
Nuvation Bio Inc. does not currently pay dividends.
Where can I find NUVB SEC filings?
Official SEC filings for Nuvation Bio Inc. (CIK: 0001811063) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NUVB's EPS?
Nuvation Bio Inc. has a diluted EPS of $-0.60.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NUVB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Nuvation Bio Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NUVB stock overvalued or undervalued?
Valuation metrics for NUVB: ROE of -66.9% (sector avg: 15%), net margin of -325.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NUVB stock in 2026?
Our dual AI analysis gives Nuvation Bio Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NUVB's free cash flow?
Nuvation Bio Inc.'s operating cash flow is $-173.4M, with capital expenditures of N/A. FCF margin is -275.7%.
How does NUVB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -325.3% (avg: 12%), ROE -66.9% (avg: 15%), current ratio 6.95 (avg: 2).